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Human immunodeficiency virus (HIV) is a subgroup of a retrovirus that causes acquired 
immunodeficiency syndrome (AIDS), which is a progressive failure of the immune system.6 
Millions of dollars have been donated for the research of HIV and how the virus works and 
effects the different systems of the body. HIV infects cells that are crucial components to the 
immune system and therefore eventually leads to the loss of cell-mediated immunity if left 
untreated.6  
The structure of the HIV retrovirus consists of two copies of single-stranded RNA, 
which produces the nine proteins that HIV expresses. Since HIV enters a wide range of cells, 
multiple tissues are negatively altered. Previous research determined the HIV-1 Transgenic (Tg) 
rat is an appropriate model for experimentation due to the fact that HIV-1 viral genes they 
expressed as well as the immune system’s response to outside invaders was very similar to 
humans.  
To determine the effects of HIV proteins, bone histomorphometry was analyzed by 
taking micron samples of the harvested cortical bones. Comparing the fluorescent bands in the 
cortical bone allowed the bone formation rate to be determined. CT (computed tomography) 
scans were taken while rats were still alive to give a visual representation of the bone. From 
evaluating microCT scans, data was collected to prove the individual cortical bone 








 35 million people worldwide currently living with Human immunodeficiency virus 
(HIV) and of those, 3.2 million are children.9 Another staggering fact, the vast majority of these 
people, specifically 71%, are in low and middle-income countries, as seen in the Figure 1. 
Human immunodeficiency virus affects 1.1 million people in the US, yet not much is known 
about the specific effects of HIV on the bone remodeling process.9 
 
HIV Structure And Function 
 










acquired immunodeficiency syndrome which is the final stage of the HIV infection. Together, 
these cause “one of the world’s most serious health and developmental challenges” (Global 
Statistics). This is due to the HIV virus’s complex structure and life cycle, which can be seen in 
Figures 2 and 3. HIV can be categorized into the group of viruses called retroviruses, meaning it 
contains the enzyme reverse transcriptase. 
This enzyme “allows the single-stranded 
RNA of the virus to be copied and double-
stranded DNA to be created” (The Structure 
and Life Cycle of HIV). HIV begins its 
invasion in the body by binding to the host 
cell, fusing with the host’s cell membrane 
and finally injecting its RNA and enzymes 
into the cell.10 From there, the HIV virus’s 
 
Figure 2: The replication cycle of HIV10 
Figure 3: HIV cell diagram7 
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DNA (provirus) gets replicated within the host’s cell, allowing the virus to invade and 
reproduce seamlessly. The HIV virus can now conquer helper T cells (or T lymphocytes, their 
main target) and eventually monocytes and macrophages.10 
There are three main ways HIV is spread: sexual contact, blood-to-blood contact, and 
passage from mother to child. Preventing the transmission of HIV is the only way to stop the 
spread and consequences of HIV/AIDS.8  
Signs And Symptoms 
HIV symptoms are unique person to person, so one cannot simply rely on symptoms to 
know if they have HIV. The only way to confirm that one is infected with HIV is to get a blood 
test.8 Some common symptoms within 2-4 weeks after exposure include flu-like symptoms: 
fever, sore throat, rash, swollen glands, fatigue and muscle and joint pain.8  
Medication And Treatment 
On the market today, around 30 Highly Active Antiretroviral Therapy (HAART) drugs 
are used to treat HIV, depending on the life cycle of the virus. There is no cure for HIV and 
taking one drug by itself will not stop HIV, so ‘cocktails’ or combinations of drugs (usually 3) 
are utilized.8 
Further Research 
Bioengineering research is needed in this developing field because the growth patterns 
of the skeleton in individuals infected with HIV, specifically in children, are unclear. Based on 
previous studies, children infected with HIV-1 have low bone density and display the negative 
effects of bone remodeling. HIV-1 transgenic rats serve as a small animal model for HIV 
infected individuals. Although the animals do not carry the virus, they do carry 7 of the 9 HIV 
genes and present with similar clinical AIDS-like symptoms by 9 months of age.3 The study 
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performed seeks to determine the effects of HIV-1 proteins on the HIV-1 transgenic rats’ bone 
growth and delicacy before all symptoms of HIV-1 appear.1 The study also investigates the 
hypothesis in which HIV-1 proteins are directly correlated with negative effects on skeletal 





 To aid in the background of my research, multiple sources of literature were accessed 
and analyzed to provide a foundation and jumping off point for my study. From Wong’s paper, 
he notes that the “HIV group had significantly lower values for all cortical bone parameters 
except average mineralization compared to the WT group,” which directly correlates with my 
research of HIV transgenic rat bone growth and gives me a foundation to build on.1  
Vikulina writes another article that highlights the bone growth differences, mainly the 
effects/complications of HIV-1- osteoporosis and bone fractures. Vikulina harps on the fact 
there are findings that confirm that reduced bone mineral density is an effect of HIV-1. The 
article goes on to target the specific molecular components of the bone remodeling process the 
“receptor activator of NF-kB ligand, the key osteoclastogenic cytokine, to its receptor 
osteoprotegerin.”3 Although complex, the molecular component that supports my current 
findings in my research of slowed or reduced bone growth and reduced bone density were found 
in HIV-1Tg rats. It also takes into account the highly active antiretroviral therapy (HAART) and 
how that may have an effect on the bone density and growth. Looking at bone growth in 
particular, HIV-1 transgenic rats undergo major bone reconstruction when infected with HIV 
type 1. This is mainly due to immune cells regulating the osteoclasts performance, so when the 
immune system is compromised with HIV, the skeleton suffers as well.3 
In Reid’s article, he presents in depth the HIV-1 transgenic rat type and how the 
phenotype of the rat can be applicable as a model for HIV-1 in humans. Specifically, the HIV 
Tg rat is very much like humans that have HIV-1 with respect to the viral genes they expressed 
as well as the immune system’s response to outside invaders. Also noteworthy, the skin and 
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muscle tissues have the most HIV-1 genes found in their cells, which is why skin lesions, 
cataracts and other characteristics displayed in the rat are very common. The RNA in the cells is 
tested in many cells to find the highest organs- the lymph nodes, spleen, kidney and thymus. 
Knowing this information makes it easier to test animal and human subjects to monitor levels of 
expression.2 
Other papers have hypothesized that as the animal changes age, the expression of the HIV 
proteins changes from peripheral immune organs to the central nervous system. At 2-3 months 
old, the rats were measured of having a much larger concentration of RNA viral protein in their 
spleens than rats that were 10-11 months old. However, the concentration of mRNA viral 
protein in the central nervous system- the cerebellum, striatum and spinal cord- in 10-11 month 
old rats was significantly higher than in 2-3 month of rats. Both of these tests prove that there 
are different viral proteins expressed at different times for different ages.5 This concept could 
explain the growth patterns that I am seeing in my research. It also takes into account the highly 
active antiretroviral therapy (HAART) and how that may have an effect on the bone density and 
growth. The technical and molecular aspect of the physical actions and traits discussed in this 





 The results compiled from the two years of research yields data to illustrate findings for 
the proposed hypothesis of slowed bone growth of HIV-1 transgenic rats. The main set of 
results is from examining and compiling data from vivaCT evaluations from alive 5, 7, and 9 
months old rats.  
Cortical Bone Thickness Comparison 
From the data collected from the vivaCT evaluations, it is easy to compile the data into a 
simple Table 1 below to see the large difference of cortical bone thickness of the femur between 
the WT and HIV rats. All measurements from the WT group were averaged, then the HIV group 
was averaged, to create the mean cortical bone thickness displayed in the table. The average 
cortical bone thickness was 0.603 
mm thick for WT rats and 0.570 
mm thick for HIV. Since the calcein 
labeling didn’t add any data to my 
research, the vivaCT evaluations 
were the foundation of my results.  
The samples embedded in 
the Polymethyl methacrylate 
(pMMA), a synthetic resin produced 
from the polymerization of methyl 























WT                 HIV 
WT vs. HIV Cortical Bone 
Thickness 
Table 1: WT vs. HIV Cortical Bone Thickness 
 8 
labeling. The rest of the slides will be used to determine the bone morphology rate and future 




The results stated previously yields data to support the proposed hypothesis of slowed 
bone growth of HIV-1 transgenic rats. The smaller average cortical bone thickness of the HIV-1 
transgenic rats indicated frailer femurs compared to the WT rat femurs. Based on background 
literature and contributing results, one can reasonably concur HIV-1 proteins may be expressed 
before symptoms are detected and influence multiple body functions at a young age. Future 
work will have to support these conclusions by comparing bone densities, weight, and survey a 
variety of ages of both HIV-1 transgenic rat and the control WT rat.1  
Significance 
This study contributes to the Guldberg lab’s HIV study as a whole, which displays the 
changes in bone growth before all symptoms of HIV-1 appear, even though HIV-1 proteins are 
expressed from birth or before birth. The microCT scans that evaluated provides data and proof 
into the effects of HIV on bone growth patterns. The result of previous microCT scans show 
that the individual cortical bone measurements in HIV-1 Tg rats is significantly less than the 
control WT rats. The long reaching effects of the studies performed can be a foundation for 
clinical trials for new HIV drugs or treatments. Knowing these growth patterns can help doctors 
treat HIV patients according to the age and progression of HIV.  
This allows all proteins to be expressed and all changes in bone growth, remodeling and 
regeneration to be completely tracked as well as osteoporosis data. This study would link 
current HIV transgenic rat studies together to see correlations between bone growth and tissue 
repair or organ growth. In addition, this research examines different bone measuring parameters 
than previously researched, which allows extension of current data and conclusions. Based on 
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these conclusions, this research fills the current gap in research of what effects the HIV 
















MATERIALS AND METHODS 
The Institutional Animal Care and Use Committee of Georgia Institute of Technology 
approved all procedures. In this study, female HIV-1 Tg rats and control wild type (WT) rats 
were used and were purchased from Harlan Laboratories. To analyze bone growth, the Tg rats 
were scanned using a vivaCT system from Scanco Medical, at 5, 7, and 9 months old. 
Histological sample processing, examination of calcein labeling, and vivaCT reconstruction 
evaluations were used to collect data that proved the hypothesis.  
VivaCT Evaluation Analysis 
VivaCT evaluations were performed on the vertebrae, distal femur, and middiaphysis. 
To determine cortical bone parameters, a 1 mm region of the femoral middiaphysis was scanned 
and evaluated. The bone parameters used from the femoral middiaphysis for further quantitative 
data were the average mineralization, cortical bone thickness, marrow area and bone area. The 
average mineralization component is the measure of attenuation, or how easily x rays are passed 
through the material. This allows researchers to compare the bone densities between the HIV-1 
Figure 4: The vivaCT reconstruction 
evaluation of sample 33941 (WT)- 
1mm section of middiaphysis  
Figure 5: The vivaCT reconstruction 
evaluation of sample 33966 (HIV)- 1mm 
section of middiaphysis  
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Tg rats and the WT rats. The vivaCT reconstruction scans of 1mm region of the femoral 
middiaphysis in both the Wild Type (WT) rats and HIV rats are shown in Figures 4 and 5 
above, respectively. In this analysis, a number of parameters are measured and output on the 
final printout of the vivaCT evaluation. 
Next, the cortical bone thickness, marrow area and bone area were evaluated and 
measured in both WT and HIV-1 transgenic rats. 
The Tb.Th (trabecular thickness) component on 
the evaluation was used to determine the 
trabecular thickness (mm), and the average 
mineralization (in the central marrow portion) 
was also measured. The data is displayed in the 
Table 2 to the right.  
 After the rats were sacrificed and the 
femurs and humeri were harvested, the samples 
were processed for histological evaluation by 
using a microtome to cut rat tibias embedded in 
blocks of pMMA (Polymethyl methacrylate). 
From trial and error this method written 
protocol did not work, so cutting pMMA block 
with a 5in diamond saw arose as an alternate 
procedure. Slices 80-200 microns thick of the sample were cut and mounted to a microscope 
slide and viewed under a microscope for observation. Since these slices of 80-200 microns were 









33556 0.5901 1331.2308 
33559 0.6304 1311.5402 
33565 0.6134 1309.1829 
33562 0.6449 1320.9695 
33626 0.5887 1307.1028 
33630 0.5931 1322.2175 
33669 0.6187 1323.1882 
33666 0.559 1313.3429 
33663 0.5945 1321.9402 
33549 0.5981 1362.5696 
33552 0.5686 1331.3695 
33568 0.5624 1329.1509 
33571 0.5817 1322.6335 
33636 0.5711 1318.7509 
33640 0.5731 1316.3936 
33648 0.5518 1329.5669 
33652 0.5838 1333.5883 
33659 0.5667 1320.8308 
33656 0.553 1304.7455 
Table 2: Data of Trabecular Thickness 
and Average Mineralization of Cortical 
bones of HIV and WT rats 
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quality of the samples. The grinding procedure began by attaching one side of the sample to a 
‘final slide’ with Technovit 7210 glue, then a ‘base slide’ was attached to the other side of the 
sample, forming a ‘sandwich.’ The sandwich was then cut with a 5in diamond saw to cut off a 
slice of a sample glued to the ‘final slide’ for further grinding. After the slide is measured, the 
slide with sample is placed on the grinder and grinded down with 1000 grit paper until the 
sample is an optimal 40-60 microns thick. The sample is then polished for clarity and used for 
further analysis and testing.  
Bone Histomorphometry Analysis 
Bone histomorphometry was analyzed and more specifically bone formation rate was 
determined by comparing the calcein-labeling fluorescent bands in the cortical bone. To create 
these bands, an initial round of calcein was injected into living HIV-1 transgenic and WT 
control rats and one week later a second round of calcein was injected again. Shortly after, the 
rats were sacrificed and the femurs from both HIV and WT control rats were harvested. The 
femurs were then embedded in pMMA for histologic analysis. From there, the 80-100 micron 
slices of the femurs were taken and placed on microscope slides. A green excitation light in the 
microscope was used to see these fluorescent bands in the cortical bone. These fluorescent 
bands are measured to determine bone formation rate by comparing the spacing in between the 
bands. Most samples did not have a distinct dual labeling appearance; so only seventeen 
samples could be analyzed for this study. In Figures 6 and 7, dual labeling can be seen with two 
layers of distinct bands. In both images, the labeling is spaced the same, so it was determined 














Figure 6: Calcein dual labeling in sample 
2101 (WT) on 1/10/14 
Figure 7: Calcein dual labeling in sample 
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